- Home
- XRAY
XRAY
DENTSPLY SIRONA Inc.
as of 03-09-2026 3:40pm EST
$12.80
+$0.03
+0.24%
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
| Founded: | 1899 | Country: | United States |
| Employees: | N/A | City: | CHARLOTTE |
| Market Cap: | 2.6B | IPO Year: | 2008 |
| Target Price: | $15.00 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | -3.00 | EPS Growth: | 33.04 |
| 52 Week Low/High: | $9.85 - $17.18 | Next Earning Date: | 05-21-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1.63% | Revenue Growth (next year): | 2.49% |
| P/E Ratio: | -4.25 | Index: | N/A |
| Free Cash Flow: | 86.0M | FCF Growth: | -62.99% |
Stock Insider Trading Activity of DENTSPLY SIRONA Inc. (XRAY)
LUCIER GREGORY T
Buy
Director
XRAY Mar 9, 2026
Avg Cost/Share
$12.45
Shares
15,000
Total Value
$186,675.00
Owned After
65,000
SEC Form 4
Forbes James D
Buy
Director
XRAY Mar 9, 2026
Avg Cost/Share
$12.48
Shares
5,000
Total Value
$62,400.00
Owned After
10,000
SEC Form 4
LUCIER GREGORY T
Buy
Director
XRAY Mar 3, 2026
Avg Cost/Share
$14.03
Shares
22,445
Total Value
$314,858.46
Owned After
65,000
SEC Form 4
Forbes James D
Buy
Director
XRAY Mar 3, 2026
Avg Cost/Share
$13.47
Shares
5,000
Total Value
$67,345.00
Owned After
10,000
SEC Form 4
LUCIER GREGORY T
Buy
Director
XRAY Mar 2, 2026
Avg Cost/Share
$14.25
Shares
27,555
Total Value
$392,520.98
Owned After
65,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LUCIER GREGORY T | XRAY | Director | Mar 9, 2026 | Buy | $12.45 | 15,000 | $186,675.00 | 65,000 | |
| Forbes James D | XRAY | Director | Mar 9, 2026 | Buy | $12.48 | 5,000 | $62,400.00 | 10,000 | |
| LUCIER GREGORY T | XRAY | Director | Mar 3, 2026 | Buy | $14.03 | 22,445 | $314,858.46 | 65,000 | |
| Forbes James D | XRAY | Director | Mar 3, 2026 | Buy | $13.47 | 5,000 | $67,345.00 | 10,000 | |
| LUCIER GREGORY T | XRAY | Director | Mar 2, 2026 | Buy | $14.25 | 27,555 | $392,520.98 | 65,000 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-1.80%
$12.48
5D
-5.20%
$12.05
20D
-5.04%
$12.07
Price: $12.71 Prob +5D: 0% AUC: 1.000
0000818479-26-000072
xray-202602260000818479false00008184792026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
February 26, 2026 Date of Report (Date of earliest event reported)
DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 0-1621139-1434669
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
13320 Ballantyne Corporate Place, Charlotte North Carolina 28277-3607
(Address of principal executive offices) (Zip Code)
(844) 848-0137 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareXRAYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On February 26, 2026, DENTSPLY SIRONA Inc. (the “Company”) issued a press release regarding the Company’s financial results for its fourth fiscal quarter and year ended December 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1.
The information contained in this Current Report on Form 8-K pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.Description
99.1 DENTSPLY SIRONA Inc. Press release issued February 26, 2026, as referenced in Item 2.02
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DENTSPLY SIRONA Inc.
By:/s/ Daniel T. Scavilla Daniel T. Scavilla President and Chief Executive Officer
Date: February 26, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0000818479-25-000254
xray-202511060000818479false00008184792025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
November 6, 2025 Date of Report (date of earliest event reported)
DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 0-1621139-1434669
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
13320 Ballantyne Corporate Place, Charlotte North Carolina 28277-3607
(Address of Principal Executive Offices) (Zip Code)
(844) 848-0137 Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareXRAYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On November 6, 2025, DENTSPLY SIRONA Inc. (the “Company”) issued a press release regarding the Company’s financial results for its third fiscal quarter ended September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1.
The information contained in this Current Report on Form 8-K pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.Description
99.1 DENTSPLY SIRONA Inc. Press release issued November 6, 2025, as referenced in Item 2.02
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DENTSPLY SIRONA Inc.
By:/s/ Daniel T. Scavilla Daniel T. Scavilla President and Chief Executive Officer
Date: November 6, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000818479-25-000152
xray-202508070000818479false00008184792025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
August 7, 2025 Date of Report (date of earliest event reported)
DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 0-1621139-1434669
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
13320 Ballantyne Corporate Place, Charlotte North Carolina 28277-3607
(Address of Principal Executive Offices) (Zip Code)
(844) 848-0137 Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareXRAYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On August 7, 2025, DENTSPLY SIRONA Inc. (the “Company”) issued a press release regarding the Company’s financial results for its second fiscal quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1.
The information contained in this Current Report on Form 8-K pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits:
Exhibit No.Description
99.1 DENTSPLY SIRONA Inc. Press release issued August 7, 2025, as referenced in Item 2.02
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DENTSPLY SIRONA Inc.
By:/s/ Matthew E. Garth Matthew E. Garth Executive Vice President and Chief Financial Officer
Date: August 7, 2025
Latest DENTSPLY SIRONA Inc. News
XRAY Breaking Stock News: Dive into XRAY Ticker-Specific Updates for Smart Investing
Insider Monkey
Dentsply Sirona (XRAY) Added by Ariel Fund as Strategic Reset Targets Long-Term Growth
📊
AI Sentiment
Positive
6/10
Compare XRAY vs Leading Stocks
See how XRAY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XRAY DENTSPLY SIRONA Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.